NFE2L2 and chronic obstructive pulmonary disease: However, when sulforaphane, an activator of Nrf2, was administrated to patients with COPD for 4 weeks, this agent increased an antioxidant gene related to Nfr2 and inhibited oxidative stress and inflammation [115].